Terray Therapeutics
Terray Therapeutics is an AI-native, chemistry-first biotechnology company building an integrated full-stack platform for small molecule drug discovery. Its EMMI platform (Experimentation Meets Machine Intelligence) pairs a proprietary ultra-miniaturized microarray assay system and fully automated lab with a family of machine learning models: COATI, a chemistry foundation model trained on roughly a billion molecules that encodes molecules into a latent space; reinforcement-learning generative models for synthesizable de novo design; TerraBind for potency prediction; and EMMI Select for uncertainty-aware molecule selection. Terray reports a proprietary target-molecule interaction dataset of more than 17 billion measurements growing by about a billion per quarter, and runs multi-target discovery collaborations with Bristol Myers Squibb, Gilead, Calico and Odyssey Therapeutics, with investment from NVIDIA. Terray publishes several of its research code libraries as open source on GitHub (COATI, COATI-LDM, TerraMax) but operates no public developer API, developer portal, or machine-readable API contract.
Terray Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Drug Discovery, Artificial Intelligence, and Machine Learning.
Terray Therapeutics’ developer surface includes engineering blog and 11 more developer resources.
Kin Score
Kin Score
How this is scored →scored 2026-08-05 · rubric v0.9.1
Security Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Agent Surfaces 1
MCP servers, agent skills, and machine-readable catalogs
Build 2
SDKs, sample code, and the tooling you integrate with
Access & Security 1
Authentication, authorization, and security posture
Operate 1
Status, limits, changes, and where to get help
Commercial 2
Pricing, plans, and the legal terms of use
Company 3
The organization behind the API
Other 2
Properties that don't map to a standard resource type